Evidence map›Paper›PMID 39017954›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

The diagnostic value of serum exosomal SNORD116 and SNORA21 for NSCLC patients.

Lin Li, Zhijun Zhang, Wei Xu, Jun Wang, Xiaodong Feng

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lin Li *Department of Pharmacy Intravenous Admixture Services, The Affiliated Taian City Central Hospital of Qingdao University, Taian, 271000, China.
Zhijun Zhang *Department of Clinical Laboratory, The Affiliated Taian City Central Hospital of Qingdao University, Taian, 271000, China.
Wei XuDepartment of Clinical Laboratory, The Affiliated Taian City Central Hospital of Qingdao University, Taian, 271000, China.
Jun WangMedical Research & Laboratory Diagnostic Center, Shandong Academy of Medical Sciences, Central Hospital Affiliated to Shandong First Medical University, 105 Jiefang Road, Jinan, 250013, China.
Xiaodong FengMedical Research & Laboratory Diagnostic Center, Shandong Academy of Medical Sciences, Central Hospital Affiliated to Shandong First Medical University, 105 Jiefang Road, Jinan, 250013, China. fxdnash@163.com.ORCID http://orcid.org/0000-0003-2700-8304

Funding

National Natural Science Foundation of China 82002226Natural Science Foundation of Shandong Province ZR2020QH283Nursery Project of the Affiliated Taian City Central Hospital of Qingdao University 2022MPM01
6 · The paper itself

Abstract

purposeNon-small cell lung cancer (NSCLC) is a widespread and serious global malignancy. This study aimed to examine the clinical relevance of serum exosomal SNORD116 and SNORA21 as novel diagnostic biomarkers for NSCLC.

methodsSerum exosomes from 226 healthy controls and 305 NSCLC patients were isolated by ultracentrifugation. Characterization of exosomes was conducted by qNano, transmission electron microscopy (TEM) and Western immunoblotting. RT-PCR revealed snoRNAs that were differentially expressed. Receiver operating characteristic (ROC) analysis was used to assess the diagnostic performance.

resultsIn NSCLC patients, the levels of serum exosomal SNORD116 and SNORA21 were significantly reduced compared to those in healthy controls (P < 0.0001 for both). ROC curves showed AUC values of 0.738 and 0.761. By combining SNORD116 and SNORA21 with traditional blood biomarkers CYFRA21-1 and carcinoembryonic antigen (CEA), the AUC increased to 0.917. Moreover, these two exosomal snoRNAs distinguished between patients with metastatic NSCLC (n = 132) and those with non-metastatic NSCLC (n = 173) significantly (P < 0.0001 for both). The ROC curves gave AUC values of 0.743 and 0.694, respectively. The combined analysis raised the AUC to 0.751. The diagnostic power of these two exosomal snoRNAs combined with CYFRA21-1 and CEA increased to 0.784.

conclusionThis study demonstrated that serum exosomal SNORD116 and SNORA21 can be used as potential promising non-invasive diagnostic biomarkers for NSCLC.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungExosomesLung NeoplasmsRNA, Small NucleolarAdultAgedAntigens, NeoplasmCarcinoembryonic AntigenCase-Control StudiesFemaleHumansKeratin-19MaleMiddle AgedROC Curveantigen CYFRA21.1Antigens, NeoplasmBiomarkers, TumorCarcinoembryonic AntigenKeratin-19RNA, Small NucleolarBiomarkersExosomesMetastasisNSCLCsnoRNAs

Identifiers

PMID39017954

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.